$MRSH

Jones John Jude sold $1.2M of MRSH

Jones John Jude (Chief Marketing Officer) sold 6,500 shares of MARSH & MCLENNAN COMPANIES, INC. (MRSH) at $191.96 ($1.25M total) on 2026-08-06.

Original reporting
SEC EDGAR · Jones John Jude
Published Aug 7, 2026, 8:03 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 8:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MRSH
Neutral
high confidence
Mentioned
$MRSH
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MRSHNeutralLow
01

Why it matters

The only new information is the reported sale size, price, and post-transaction holdings by the CMO. There is no accompanying corporate action or guidance change.

02

Market read

Traders may monitor insider activity for sentiment, but this specific disclosure lacks fundamental catalysts in the provided text.

03

What to watch

The article does not state whether the sale was part of a 10b5-1 plan (it says no), but it also provides no context on compensation, tax obligations, or prior holdings beyond the post-transaction share count.

Relevance 6/10Novelty 3/10Timing: filed Aug 7, 2026 after-hours (20:03:42 UTC)

Background

The article is an SEC Form 4 insider transaction disclosure for Marsh & McLennan (MRSH).

Company-level read

Ticker impact

$MRSHNeutralHigh confidence
Context

Marsh & McLennan CMO Jones John Jude sold 6,500 shares in an open-market transaction worth about $1.25M, per a fresh Form 4 filing.

Expected impact

Low near-term impact; any reaction is likely limited unless accompanied by unusual volume or additional disclosures.

Evidence & confidence

The filing is a routine insider transaction (open-market sale) with no 10b5-1 plan and no accompanying guidance, contract, or regulatory event in the text.

Market effects

No clear sector read-through from a single routine insider sale.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-planned liquidity needs, so the signal may be overstated.

Key entities

  • Marsh & McLennan Companies, Inc.

    Subject of the Form 4 insider sale disclosure (MRSH).

  • Jones John Jude

    Chief Marketing Officer who sold 6,500 shares in an open-market transaction.

Related articles

$MRSHMed

Marsh & McLennan Companies Q2 Earnings Call Highlights

Marsh & McLennan (NYSE:MRSH) reported Q2 results and discussed market conditions on its earnings call. Consulting revenue rose 10% to $2.6B, with adjusted operating income up 11% to $533M. Mercer revenue was $1.6B. Marsh Global Insurance Market Index showed primary commercial rates down 6% in Q2. The company ended with $20.6B debt and $1.7B cash, and expects $5.5B capital deployment in 2026.

$MRSHMed

Marsh (NYSE:MRSH) Exceeds Q2 CY2026 Expectations

Marsh (NYSE:MRSH) reported Q2 CY2026 results. Revenue rose 6.2% year on year to $7.40 billion, exceeding Wall Street’s estimate by 1.8%, and non-GAAP EPS was $2.96, 2.3% above consensus. Adjusted operating margin was 26.9%. Analysts expect revenue growth of 4.2% and full-year EPS to rise from $10.22 to $10.90.

$MRSHMed

MARSH & MCLENNAN COMPANIES, INC. (MRSH): Results of Operations and Financial Condition

MARSH & MCLENNAN COMPANIES, INC. (MRSH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 mmc2q2026ex991newsrelease.htm PRESS RELEASE JUNE 30, 2026 Document Marsh 212 345 5000 www.corporate.marsh.com News release Exhibit 99.1 Marsh reports second quarter 2026 results • Revenue Growth of 6%; Underlying Revenue Growth of 5% • GAAP Operating Income Increases 4%

$MRSHHighAI 9/10

Marsh & McLennan Companies (NYSE:MRSH) Stock Price Down 13.1% After Analyst Downgrade

Marsh & McLennan (NYSE:MRSH) fell 13.1% mid-day Wednesday after Piper Sandler cut its price target to $182 from $190 and kept a neutral rating. Shares traded as low as $180.97 and last at $160.70, after closing $185.00; volume rose to 3.04M. The article also cites recent analyst target changes and April 16 quarterly results: $3.29 EPS vs $3.21 consensus on $7.30B revenue.